Atika Capital Management LLC Purchases Shares of 12,350 United Therapeutics Corporation $UTHR

Atika Capital Management LLC bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 1st quarter, Holdings Channel.com reports. The institutional investor bought 12,350 shares of the biotechnology company’s stock, valued at approximately $7,323,000. United Therapeutics accounts for 0.9% of Atika Capital Management LLC’s holdings, making the stock its 27th largest position.

Other large investors also recently added to or reduced their stakes in the company. Torren Management LLC purchased a new position in United Therapeutics during the fourth quarter valued at $26,000. Activest Wealth Management increased its holdings in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC lifted its stake in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics during the 4th quarter valued at about $31,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. lifted their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. HC Wainwright increased their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Finally, Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $648.33.

Insiders Place Their Bets

In other United Therapeutics news, Director Jan Malcolm sold 325 shares of the business’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $550.59, for a total transaction of $178,941.75. Following the completion of the transaction, the director owned 450 shares in the company, valued at $247,765.50. The trade was a 41.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $535.99, for a total value of $5,091,905.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $21,714,562.87. This represents a 19.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 513,333 shares of company stock valued at $286,933,042 over the last 90 days. Insiders own 8.60% of the company’s stock.

United Therapeutics Stock Up 0.5%

NASDAQ UTHR opened at $529.53 on Friday. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The firm has a market capitalization of $22.48 billion, a price-to-earnings ratio of 19.55, a PEG ratio of 1.76 and a beta of 0.58. The company has a fifty day moving average of $548.68 and a two-hundred day moving average of $531.41.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the prior year, the firm posted $6.63 earnings per share. Equities research analysts anticipate that United Therapeutics Corporation will post 26.63 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.